ELAN: Novartis andaba "detrás de ella" pero J&J se la quedó...

Más...

Pocos días después de la noticia anterior se confirmó la compra por parte de J&J.
En el fondo de la operación está el interés por el portafolio de productos de la compañía irlandesa en Alzheimer.

Elan's focus on improving the health of patients suffering from chronic and debilitating conditions is exemplified by its breakthrough research program in Alzheimer's disease, where it has developed three novel therapeutic approaches:

• Immunotherapy In collaboration with Wyeth, this approach targets the clearance of beta-amyloid, the peptide responsible for the build-up of amyloid plaques in the brain
  
• Beta secretase inhibitors Targets a distinct enzyme associated with the production of beta-amyloid
  
• Gamma secretase inhibitors Targets a distinct enzyme associated with the production of beta-amyloid

ELAN

Key Facts

Locations:

• Athlone, Ireland
• Bermuda
• Dublin, Ireland (headquarters)
• Gainesville, Georgia
• King of Prussia, Pennsylvania
• South San Francisco, California
• Tokyo, Japan

Employees

• Approximately 1,600 worldwide

CEO

• G. Kelly Martin

Más...